Sorafenib Induced Hand and Foot Syndrome

Abstract:

Sorafenib a multikinase inhibitor has been approved by the FDA for the treatment of thyroid, hepatocellular and renal cell carcinoma. Hand-foot syndrome / palmar – plantar erythrodysesthesia causes redness, swelling and pain on the palms of the hands and / or the soles of the feet. Sometimes blisters also appear. Here, we report a post right hepatectomy hepatocellular carcinoma patient who developed hand and foot syndrome after a dose with sorafenib.

Key words: Sorafenib, Hand and Foot Syndrome, Multikinase Inhibitor, Hepatocellular, Carcinoma.